Jeffrey L. Silber

6.2k total citations · 1 hit paper
31 papers, 1.9k citations indexed

About

Jeffrey L. Silber is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Jeffrey L. Silber has authored 31 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 11 papers in Infectious Diseases and 5 papers in Pharmacology. Recurrent topics in Jeffrey L. Silber's work include Herpesvirus Infections and Treatments (13 papers), Clostridium difficile and Clostridium perfringens research (6 papers) and Influenza Virus Research Studies (5 papers). Jeffrey L. Silber is often cited by papers focused on Herpesvirus Infections and Treatments (13 papers), Clostridium difficile and Clostridium perfringens research (6 papers) and Influenza Virus Research Studies (5 papers). Jeffrey L. Silber collaborates with scholars based in United States, Canada and Japan. Jeffrey L. Silber's co-authors include Ivan S. F. Chan, Katia Schlienger, Annette C. Reboli, Lily Lee, Nita L. Seibel, John R. Perfect, Gary Horwith, Mark J. DiNubile, John W. Hiemenz and John Lister and has published in prestigious journals such as JAMA, Nature Medicine and Annals of Internal Medicine.

In The Last Decade

Jeffrey L. Silber

29 papers receiving 1.8k citations

Hit Papers

VE303, a Defined Bacteria... 2023 2026 2024 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection
    2023 120 citations Thomas Louie, Yoav Golan et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey L. Silber United States 16 1.4k 860 266 237 184 31 1.9k
Robert W. Bradsher United States 29 2.9k 2.0× 2.6k 3.0× 182 0.7× 122 0.5× 103 0.6× 85 3.8k
Toshiaki Ihara Japan 22 1.2k 0.9× 384 0.4× 70 0.3× 68 0.3× 70 0.4× 106 1.6k
Florence Morfin France 30 1.8k 1.2× 969 1.1× 48 0.2× 227 1.0× 48 0.3× 83 2.8k
Jin Han Kang South Korea 24 984 0.7× 693 0.8× 59 0.2× 214 0.9× 57 0.3× 203 2.0k
F. Foulet France 27 1.1k 0.8× 958 1.1× 380 1.4× 162 0.7× 27 0.1× 56 1.7k
P.A.C. Maple United Kingdom 23 829 0.6× 602 0.7× 74 0.3× 48 0.2× 81 0.4× 59 1.7k
Bruce L. Gilliam United States 21 540 0.4× 744 0.9× 78 0.3× 148 0.6× 35 0.2× 62 1.5k
Joseph Wheat United States 23 1.8k 1.2× 1.5k 1.8× 111 0.4× 140 0.6× 20 0.1× 38 2.2k
N. Manca Italy 24 664 0.5× 425 0.5× 275 1.0× 172 0.7× 23 0.1× 80 1.8k
Anthony Allworth Australia 21 739 0.5× 610 0.7× 109 0.4× 104 0.4× 17 0.1× 34 1.6k

Countries citing papers authored by Jeffrey L. Silber

Since Specialization
Citations

This map shows the geographic impact of Jeffrey L. Silber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey L. Silber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey L. Silber more than expected).

Fields of papers citing papers by Jeffrey L. Silber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey L. Silber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey L. Silber. The network helps show where Jeffrey L. Silber may publish in the future.

Co-authorship network of co-authors of Jeffrey L. Silber

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey L. Silber. A scholar is included among the top collaborators of Jeffrey L. Silber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey L. Silber. Jeffrey L. Silber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Menon, Rajita, Shakti K. Bhattarai, Emily Crossette, et al.. (2025). Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection. Nature Medicine. 31(1). 223–234. 10 indexed citations
2.
Bloom, Patricia P., Christine M. Bassis, Emily Crossette, et al.. (2025). Safety and efficacy of a defined bacterial consortium, VE303, to treat HE. Hepatology Communications. 9(3). 1 indexed citations
3.
Schram, Alison M., Naoko Takebe, Qin Zhou, et al.. (2025). A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors. ESMO Open. 10(9). 105569–105569.
4.
Louie, Thomas, Yoav Golan, Sahil Khanna, et al.. (2023). VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection. JAMA. 329(16). 1356–1356. 120 indexed citations breakdown →
5.
Menon, Rajita, Emily Crossette, Shakti K. Bhattarai, et al.. (2022). 890: RAPID AND DURABLE COLONIZATION OF VE303 IN CLOSTRIDIODES DIFFICILE INFECTION (CDI) PATIENTS IS ASSOCIATED WITH CLINICAL EFFICACY: RESULTS OF THE PHASE 2 CONSORTIUM STUDY. Gastroenterology. 162(7). S–217. 1 indexed citations
6.
Parrino, Janie, Jon E. Stek, Kathleen Coll, et al.. (2015). Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 33(27). 3129–3134. 26 indexed citations
7.
Tyring, Stephen K., Jon E. Stek, Jeffrey G. Smith, et al.. (2012). Varicella-Zoster Virus-Specific Enzyme-Linked Immunospot Assay Responses and Zoster-Associated Pain in Herpes Zoster Subjects. Clinical and Vaccine Immunology. 19(9). 1411–1415. 7 indexed citations
8.
Lange, Joep M. A., Stephen K. Tyring, Gregory A. Poland, et al.. (2011). Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 30(5). 904–910. 50 indexed citations
9.
10.
Tyring, Stephen K., Myron J. Levin, Janie Parrino, et al.. (2010). Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 28(25). 4204–4209. 51 indexed citations
11.
Manoff, Susan B., Charles Liss, Michael J. Caulfield, et al.. (2010). Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years. The Journal of Infectious Diseases. 201(4). 525–533. 58 indexed citations
12.
Sutradhar, Santosh, Katia Schlienger, Jon E. Stek, et al.. (2009). Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older. Clinical and Vaccine Immunology. 16(5). 646–652. 25 indexed citations
13.
Silber, Jeffrey L., et al.. (2007). Immunogenicity of Oka/Merck Varicella Vaccine in Children Vaccinated at 12–14 Months of Age Versus 15–23 Months of Age. The Pediatric Infectious Disease Journal. 26(7). 572–576. 13 indexed citations
14.
Guzmán, Manuel, Jaynier Moya, Katia Schlienger, et al.. (2006). Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine. 25(11). 2139–2144. 33 indexed citations
15.
16.
Levin, Myron J., Jeffrey G. Smith, Robin M. Kaufhold, et al.. (2003). Decline in Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity with Increasing Age and Boosting with a High‐Dose VZV Vaccine. The Journal of Infectious Diseases. 188(9). 1336–1344. 233 indexed citations
17.
Walsh, Thomas J., John W. Hiemenz, Nita L. Seibel, et al.. (1998). Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 Cases. Clinical Infectious Diseases. 26(6). 1383–1396. 461 indexed citations
18.
Silber, Jeffrey L.. (1996). Rocky Mountain spotted fever. Clinics in Dermatology. 14(3). 245–258. 12 indexed citations
19.
Winston, Drew J., Pranatharthi Chandrasekar, Hillard M. Lazarus, et al.. (1993). Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial. Annals of Internal Medicine. 118(7). 495–503. 312 indexed citations
20.
Kumar, Lokender, G. Schwarz, & Jeffrey L. Silber. (1993). Acinetobacter anitratus (AA) bacteremia: A five year review. American Journal of Infection Control. 21(2). 101–101. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert W. Bradsher Breakdown of academic impact, for papers by Toshiaki Ihara Breakdown of academic impact, for papers by Florence Morfin Breakdown of academic impact, for papers by Jin Han Kang Breakdown of academic impact, for papers by F. Foulet Breakdown of academic impact, for papers by P.A.C. Maple Breakdown of academic impact, for papers by Bruce L. Gilliam Breakdown of academic impact, for papers by Joseph Wheat Breakdown of academic impact, for papers by N. Manca Breakdown of academic impact, for papers by Anthony Allworth
Rankless by CCL
2026